Liquid biopsies: the future of cancer diagnosis?
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
ADA 2019 – a good start for Beta Bionics
The iLet system showed decent blood sugar control in its first trial, but the highly automated system is far from proven.
Rewalk Robotics suits up
Europe and the US approvals of the ReStore device have arrived within a week; now the company must deliver commercially.
MD Start bucks the trend for later-stage medtech investing
Backed by big medtech including Medtronic, MD Start aims not just to incubate start-ups but to create new device companies from scratch.
Thrive emerges with cash, a cancer blood test, and a plan
A new player has entered the liquid biopsy game.
Abbott shifts to tricuspid repair
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?
Asco 2019 – Guardant and Grail square up
Two closely-watched liquid biopsy developers are to present data on their respective solid tumour blood tests.
Exact falls on Guardant’s liquid biopsy plans
The mere possibility of Guardant horning in on colorectal cancer has spooked Exact’s investors.
Boston buys Vertiflex without investing first
A poor quarter is followed by an acquisition, but is it big enough?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.